Certain medical marijuana products moved to Schedule III as broader review begins.
The Justice Department (DOJ) and Drug Enforcement Administration (DEA) announced that FDA-approved products containing marijuana—along with marijuana products regulated under qualifying state medical marijuana licenses—would be placed in Schedule III of the Controlled Substances Act. Officials also said a new administrative hearing process will begin June 29, 2026, to consider broader federal rescheduling of marijuana from Schedule I to Schedule III.
DEA Administrator Terry Cole said the agency is “expeditiously moving forward with the administrative hearing process — bringing consistency and oversight to an area that has lacked both.”
The announcement stated that the prior hearing process, begun in 2024, is being withdrawn and replaced with a new timetable intended to expedite review while following federal law.
As the Lord Leads, Pray with Us…
- For Administrator Cole and DEA officials to be wise as they enact policy changes.
- For Acting Attorney General Blanche and law enforcement agents as they address trafficking, addiction, and public safety risks.
- For federal researchers as they provide evidence for physicians and patients regarding treatment options.
Sources: Department of Justice
